| abstract |
The present invention relates to a compound having the following formula (I), which may be in the form of a base or in the form of a hydrate or a solvate, which is used in combination with prednisone or prednisolone. Castration-resistant or hormone-refractory metastatic prostate cancer for patients who do not have a risk of developing a gastrointestinal disorder selected from the group consisting of gastrointestinal bleeding and perforation, gastritis, enterocolitis, neutropenic reduced intestinal Colitis, colitis, intestinal obstruction, and intestinal congestion. |